Form 4: Maze Therapeutics SVP Sells Shares Under 10b5-1 Plan

Amy Bachrodt, SVP of Finance at Maze Therapeutics, executed option exercises and subsequent sales of common stock totaling 5,000 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Amy Bachrodt, SVP of Finance at Maze Therapeutics, Inc. (MAZE), reported transactions involving the company's common stock.
• On February 2, 2026, Bachrodt exercised stock options to acquire 4,844 shares of common stock at an exercise price of $10.42 per share.
• Concurrently, on February 2, 2026, Bachrodt exercised stock options to acquire an additional 156 shares of common stock at an exercise price of $10.42 per share.
• Following the exercises, Bachrodt sold a total of 5,000 shares of common stock in multiple transactions.
• Sales included 200 shares at $44.15, 4,064 shares at a weighted average price of $46.0305 (ranging from $45.345 to $46.34), and 736 shares at a weighted average price of $46.6323 (ranging from $46.365 to $47.23).
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• After these transactions, Bachrodt beneficially owns 12,965 shares of non-derivative common stock.
• Bachrodt also holds 3,025 stock options with an exercise price of $10.42 and an expiration date of February 17, 2032, and 41,333 stock options with an exercise price of $10.42 and an expiration date of December 8, 2034.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, which is generally neutral. The sales at significantly higher prices indicate profitability for the insider, reflecting the value of their compensation.

Positives

• The insider exercised options at a significantly lower price ($10.42) and sold shares at much higher prices (ranging from $44.15 to $47.23), indicating a profitable transaction for the individual.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests pre-planned personal financial management rather than opportunistic trading based on non-public information.

Negatives

• The sale of 5,000 shares by a Senior Vice President of Finance could be perceived by some investors as a lack of confidence, although the 10b5-1 plan mitigates this concern.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by executives, are a common occurrence in the biotechnology and pharmaceutical sectors as options vest and individuals manage personal financial planning and portfolio diversification. The use of a Rule 10b5-1 plan for these transactions is standard practice, indicating pre-scheduled sales and generally reducing concerns about opportunistic trading based on material non-public information.

Stakeholder Impact

• Shareholders may observe the insider selling shares, but the pre-arranged 10b5-1 plan typically mitigates concerns about the timing or motivation of the sales, suggesting personal financial management rather than a negative outlook on the company.

Next Steps

• The remaining 41,333 stock options will continue to vest monthly, subject to the reporting person's continued service to the Issuer.

Key Dates

Recommendation

The filing details routine insider transactions (option exercises and sales) executed under a pre-established 10b5-1 trading plan. This type of transaction is common for executives managing personal finances and diversifying holdings, and does not typically signal a change in the company's fundamental outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Maze Therapeutics, MAZE, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Amy Bachrodt, SVP Finance